A practical reference on drug affinity complex: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
== Business development == In 2002, BioMarin acquired Glyko Biomedical. In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse. In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia. In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
Sulfo-NHS esters are more soluble in water and should be dissolved in water just before use because they hydrolyze easily. The water solubility of sulfo-NHS-esters stems from their sulfonate group on the N-hydroxysuccinimide ring and eliminates the need to dissolve the reagent in an organic solvent. Sulfo-NHS-esters of biotin also can be used as cell surface biotinylation reagents, because they do not penetrate the cell membrane. The chemical reactions of NHS- and sulfo-NHS esters are essentially identical, in that they both react spontaneously with amines to form an amide bond. Because the target for the ester is a deprotonated primary amine, the reaction is favored under basic conditions (above pH 7). Hydrolysis of the NHS ester is a major competing reaction, and the rate of hydrolysis increases with increasing pH. NHS- and sulfo-NHS-esters have a half-life of several hours at pH 7 but only a few minutes at pH 9. There is some flexibility in the conditions for conjugating NHS-esters to primary amines. Incubation temperatures can range from 4-37 °C, pH values in the reaction range from 7–9, and incubation times range from a few minutes to 12 hours. Buffers containing amines (such as Tris or glycine) must be avoided, because they compete with the reaction.
=== ATP binding cassette transporter === Transporting chemicals out of a cell against a gradient is often associated with ATP hydrolysis. Transport is mediated by ATP binding cassette transporters. The human genome encodes 48 ABC transporters, that are used for exporting drugs, lipids, and other compounds.
The mechanical equivalence principle was first stated in its modern form by the German surgeon Julius Robert von Mayer in 1842. Mayer reached his conclusion on a voyage to the Dutch East Indies, where he found that his patients' blood was a deeper red because they were consuming less oxygen, and therefore less energy, to maintain their body temperature in the hotter climate. He discovered that heat and mechanical work were both forms of energy, and in 1845, after improving his knowledge of physics, he published a monograph that stated a quantitative relationship between them.
Sources: en.wikipedia.org
A syringe is a simple reciprocating pump consisting of a plunger (though in modern syringes, it is actually a piston) that fits tightly within a cylindrical tube called a barrel. The plunger can be linearly pulled and pushed along the inside of the tube, allowing the syringe to take in and expel liquid or gas through a discharge orifice at the front (open) end of the tube. The open end of the syringe may be fitted with a hypodermic needle, a nozzle or tubing to direct the flow into and out of the barrel. Syringes are frequently used in clinical medicine to administer injections, infuse intravenous therapy into the bloodstream, apply compounds such as glue or lubricant, and draw/measure liquids. There are also prefilled syringes (disposable syringes marketed with liquid inside). The word "syringe" is derived from the Greek σῦριγξ (syrinx, meaning "Pan flute", "tube").
It has been proposed that the key event in polymerization is probably the propagation of a conformational change from the centre of the bond with the nucleotide to this domain, which changes from a loop to a spiral. However, this hypothesis has been refuted by other studies.
Several Latin American and Caribbean countries have, at times, faced allegation governments involvement in the illegal drug trade the 1970s and 1980s.In 1978 and 1980, so called "cocaine coups" in Honduras and Bolivia brought such governments to power that were linked to drug trafficking networks (see illegal drug trade in Honduras and illegal drug trade in Bolivia). In Panama, Manuel Noriega, a long-term drug trafficker, served as a head of military from 1983 to 1989, during which he maintained ties with the CIA. The Colombian parapolitics scandal revealed links between parts of the Colombian establishment and the United Self-Defense Forces of Colombia (AUC), a paramilitary group responsible for killing tens of thousands of Colombian civilians, which controls over 75% of the Colombian cocaine trade. The illegal drug trade in Peru was until 2000 shaped by Vladimiro Montesinos's involvement; he had been head of the country's intelligence service since 1990. In 2010 it was alleged that the Mexican Sinaloa cartel had used bribery to co-opt the federal government and focus the government's anti-drug efforts on its competitors. According to Peter Dale Scott, "The Guadalajara Cartel, Mexico's most powerful drug-trafficking network in the early 1980s, prospered largely because it enjoyed the protection of the DFS, under its chief Miguel Nazar Haro, a CIA asset." Now, in the 21st century, there are still major issues with government corruption in Latin America.
Sources: en.wikipedia.org
September 10, 2010: Canada Statistics Canada said an additional 36,000 people got jobs in August, but the unemployment rate rose 0.1 percentage points, to 8.1%, as a larger number of people sought work. That raised the number of unemployed by 17,800, to slightly more than 1.5 million. Excluding the bounce in education jobs, employment actually fell by about 32,000, economists at BMO Capital Markets and CIBC said.
=== Historical Use of Insects in Medicine === The medicinal application of insects dates back to ancient civilizations. The Smithsonian Institution has documented historical uses of insects such as the utilization of bee venom therapy in Egyptian medicine for treating arthritis and joint pain. Ancient Greek and Roman physicians, including Galen, recorded the use of insects like cantharidin from blister beetles for dermatological conditions. In medieval Europe powdered insects were included in remedies for various ailments including infections and respiratory disorders.
== Structural studies == As of late 2007, 9 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1G6K, PDB: 1GCO, PDB: 1GEE, PDB: 1RWB, PDB: 1SPX, PDB: 2B5V, PDB: 2B5W, PDB: 2CD9, and PDB: 2CDA.
Smallpox was not notably infectious in the prodromal period and viral shedding was usually delayed until the appearance of the rash, which was often accompanied by lesions in the mouth and pharynx. The virus can be transmitted throughout the course of the illness, but this happened most frequently during the first week of the rash when most of the skin lesions were intact. Infectivity waned in 7 to 10 days when scabs formed over the lesions, but the infected person was contagious until the last smallpox scab fell off. Concern about possible use of smallpox for biological warfare led in 2002 to Donald K. Milton's detailed review of existing research on its transmission and of then-current recommendations for controlling its spread. He agreed, citing Rao, Fenner and others, that "careful epidemiologic investigation rarely implicated fomites as a source of infection"; noted that "Current recommendations for control of secondary smallpox infections emphasize transmission 'by expelled droplets to close contacts (those within 6–7 feet)'"; but warned that the "emphasis on spread via large droplets may reduce the vigilance with which more difficult airborne precautions [i.e. against finer droplets capable of traveling longer distances and penetrating deeply into the lower respiratory tract] are maintained".
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.